PhD Position in Translational Immunotherapy and T Cell-Based Cancer Research

The Translational Immunotherapy research group at the Department of Hematology, Oncology and Cell Therapy, Otto von Guericke University Magdeburg, is recruiting a doctoral researcher (PhD student) to join their dynamic and growing team. The group, led by Professor Matthias Leisegang, focuses on developing innovative T cell receptor (TCR)-based T cell therapies for cancer, utilizing state-of-the-art molecular, immunological, and single-cell technologies. Research activities span from basic science to clinical translation, with a strong emphasis on tumor immunology, T cell assays, and bioinformatics. The doctoral project will involve contributing to translational research projects, including the identification, cloning, and functional analysis of TCR genes from single cells, high-throughput sequencing, and the use of in vitro and in vivo models (including syngeneic mouse cancer models). The candidate will also engage in bioinformatic processing of sequencing data, animal experimentation, and the publication and presentation of scientific results at national and international conferences. The group collaborates internationally, including with the David and Etta Jonas Center for Cellular Therapy in Chicago. Applicants should hold an excellent Master’s degree in Biology, Biochemistry, Immunology, Molecular Medicine, or a related field, with strong knowledge in cell biology, immunology, or molecular biology. Experience with cell culture, T cell assays, cloning, sequencing, bioinformatics, and animal experimentation is desirable. Candidates should be highly motivated, able to work independently and in interdisciplinary teams, and possess very good English skills. The position is third-party funded, compensated according to TV-L E13 (65%), and initially limited until December 31, 2027, with the possibility of extension. The research environment offers access to modern laboratory infrastructure, close scientific supervision, and opportunities for professional development and international collaboration. Additional benefits include training opportunities, discounted public transport, and workplace health programs. Applications are due by February 1, 2026. Interested candidates should apply via the university’s application portal, by email, or by post, referencing the appropriate reference number. For further inquiries, Professor Matthias Leisegang can be contacted by phone. The university encourages applications from women and individuals with disabilities.